LeonaBio

LeonaBio Operating Cash Flow

The Operating Cash Flow of LeonaBio (LONA) as of Nov 5, 2026 is -45.73 M USD. In the previous year, Operating Cash Flow was -97.17 M USD — a change of -52.94% (higher).

Operating Cash Flow

-45.73 MUSD

YoY

-52.94%

Last updated:

Operating Cash Flow of LeonaBio is 2025 -45.73 M USD. Operating Cash Flow of LeonaBio was 2024 -97.17 M USD. It decreases by -52.94% higher compared to the previous year.

The LeonaBio Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-4.48 M USD
Jan 1, 2019
-3.71 M USD
Jan 1, 2020
-24.11 M USD
Jan 1, 2021
-43.10 M USD
Jan 1, 2022
-72.47 M USD
Jan 1, 2023
-100.75 M USD
Jan 1, 2024
-97.17 M USD
Jan 1, 2025
-45.73 M USD
The LeonaBio Operating Cash Flow history
YEAROperating Cash FlowYoY
-45.73 MUSD-52.94%
-97.17 MUSD-3.56%
-100.75 MUSD+39.03%
-72.47 MUSD+68.15%
-43.10 MUSD+78.73%
-24.11 MUSD+549.42%
-3.71 MUSD-17.18%
-4.48 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Operating Cash Flow of LeonaBio is -45.73 M USD in 2025.

Operating Cash Flow of LeonaBio changed from -97.17 M USD to -45.73 M USD, representing a -52.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — LeonaBio

All Key Metrics — LeonaBio